What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials

European Neuropsychopharmacology

Volumn 17, Issue 11, 2007, Pages 696-707

  Berlim, Marcelo T ^a   Turecki, Gustavo ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Diagnosis; Methodology; Systematic review; Unipolar depression

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; COCHRANE LIBRARY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; DRUG RESPONSE; EMBASE; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; NOMENCLATURE; PEER REVIEW; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCINFO; REVIEW; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; HUMANS; MEDLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 34548773850     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.03.009     Document Type: Review

References (76)

1. Ananth J. Treatment-resistant depression. Psychother. Psychosom. 67 (1998) 61-70
2. Avery D.H., Claypoole K., Robinson L., Neumaier J.F., Dunner D.L., Scheele L., Wilson L., and Roy-Byrne P. Repetitive transcranial magnetic stimulation in the treatment of medication-resistant depression: preliminary data. J. Nerv. Ment. Dis. 187 (1999) 114-117
3. Avery D.H., Holtzheimer III P.E., Fawaz W., Russo J., Neumaier J., Dunner D.L., Haynor D.R., Claypoole K.H., Wajdik C., and Roy-Byrne P. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol. Psychiatry 59 (2006) 187-194
4. Barbosa L., Berk M., and Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J. Clin. Psychiatry 64 (2003) 403-407
5. Baumann P., Nil R., Souche A., Montaldi S., Baettig D., Lambert S., Uehlinger C., Kasas A., Amey M., and Jonzier-Perey M. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J. Clin. Psychopharmacol. 16 (1996) 307-314
6. Berman R.M., Narasimhan M., and Charney D.S. Treatment-refractory depression: definitions and characteristics. Depress. Anxiety 5 (1997) 154-164
7. Berman R.M., Narasimhan M., Sanacora G., Miano A.P., Hoffman R.E., Hu X.S., Charney D.S., and Boutros N.N. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol. Psychiatry 47 (2000) 332-337
8. Bird D., Haddad P.M., and Dursun S.M. An overview of the definition and management of treatment-resistant depression. Klin. Psikofarmakol. Bul. 12 (2002) 92-101
9. Birkenhager T.K., van den Broek W.W., Mulder P.G., Bruijn J.A., and Moleman P. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in AD-refractory depressed inpatients. J. Clin. Psychiatry 65 (2004) 1505-1510
10. Boutros N.N., Gueorguieva R., Hoffman R.E., Oren D.A., Feingold A., and Berman R.M. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Res. 113 (2002) 245-254
11. Burrows G.D., and Norman T.R. Treatment-resistant unipolar depression. In: Lader M., and Naber D. (Eds). Difficult Clinical Problems in Psychiatry (1999), Martin Dunitz, London 57-73
12. Fagiolini A., and Kupfer D.J. Is treatment-resistant depression a unique subtype of depression?. Biol. Psychiatry 53 (2003) 640-648
13. Fava M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 53 (2003) 649-659
14. Fava M., and Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatry Clin. North Am. 19 (1996) 179-200
15. Fava M., and Rush A.J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother. Psychosom. 75 (2006) 139-153
16. Fink M. A trial of ECT is essential before a diagnosis of refractory depression is made. In: Amsterdam J.D. (Ed). Advances in Neuropsychiatry and Psychopharmacology (1991), Raven Press, New York 87-92
17. Fitzgerald P.B., Brown T.L., Marston N.A., Daskalakis Z.J., De Castella A., and Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 60 (2003) 1002-1008
18. Fitzgerald P.B., Benitez J., de Castella A., Daskalakis Z.J., Brown T.L., and Kulkarni J. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am. J. Psychiatry 163 (2006) 88-94
19. Folkerts H.W., Michael N., Tolle R., Schonauer K., Mucke S., and Schulze-Monking H. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression - a randomized study. Acta Psychiatry Scand. 96 (1997) 334-342
20. Frye M.A., Ketter T.A., Kimbrell T.A., Dunn R.T., Speer A.M., Osuch E.A., Luckenbaugh D.A., Cora-Ocatelli G., Leverich G.S., and Post R.M. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol. 20 (2000) 607-614
21. Garcia-Toro M., Segura C., Gonzalez A., Perello J., Valdivia J., Salazar R., Tarancon G., Campoamor F., Salva J., De La Fuente L., and Romera M. Inefficacy of burst-suppression anesthesia in medication-resistant major depression: a controlled trial. J. ECT 17 (2001) 284-288
22. Garcia-Toro M., Mayol A., Arnillas H., Capllonch I., Ibarra O., Crespi M., Mico J., Lafau O., and Lafuente L. Modest adjunctive benefit with transcranial magnetic stimulation in medication-resistant depression. J. Affect. Disord. 64 (2001) 271-275
23. Garcia-Toro M., Salva J., Daumal J., Andres J., Romera M., Lafau O., Echevarria M., Mestre M., Bosch C., Collado C., Ibarra O., and Aguirre I. High (20-Hz) and low (1-Hz) frequency transcranial magnetic stimulation as adjuvant treatment in medication-resistant depression. Psychiatry Res. 146 (2006) 53-57
24. Grunhaus L., Schreiber S., Dolberg O.T., Polak D., and Dannon P.N. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol. Psychiatry 53 (2003) 324-331
25. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
26. Heresco-Levy U., Javitt D.C., Gelfin Y., Gorelik E., Bar M., Blanaru M., and Kremer I. Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J. Affect. Disord. 93 (2006) 239-243
27. Kauffmann C.D., Cheema M.A., and Miller B.E. Slow right prefrontal transcranial magnetic stimulation as a treatment for medication-resistant depression: a double-blind, placebo-controlled study. Depress. Anxiety 19 (2004) 59-62
28. Keller M.B. Issues in treatment-resistant depression. J. Clin. Psychiatry 66 suppl 8 (2005) 5-12
29. Landen M., Bjorling G., Agren H., and Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J. Clin. Psychiatry 59 (1998) 664-668
30. Loo C., Mitchell P., Sachdev P., McDarmont B., Parker G., and Gandevia S. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am. J. Psychiatry 156 (1999) 946-948
31. Loo C.K., Mitchell P.B., Croker V.M., Malhi G.S., Wen W., Gandevia S.C., and Sachdev P.S. Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimulation for the treatment of resistant major depression. Psychol. Med. 33 (2003) 33-40
32. Maes M., Vandoolaeghe E., and Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J. Affect. Disord. 41 (1996) 201-210
33. Maes M., Libbrecht I., van Hunsel F., Campens D., and Meltzer H.Y. Pindolol and mianserin augment the AD activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19 (1999) 177-182
34. Malison R.T., Anand A., Pelton G.H., Kirwin P., Carpenter L., McDougle C.J., Heninger G.R., and Price L.H. Limited efficacy of ketoconazole in treatment-refractory major depression. J. Clin. Psychopharmacol. 19 (1999) 466-470
35. Manes F., Jorge R., Morcuende M., Yamada T., Paradiso S., and Robinson R.G. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly. Int. Psychogeriatr. 13 (2001) 225-231
36. Marangell L.B., George M.S., Callahan A.M., Ketter T.A., Pazzaglia P.J., L'Herrou T.A., Leverich G.S., and Post R.M. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch. Gen. Psychiatry 54 (1997) 214-222
37. Merriam-Webster's Collegiate Dictionary. 11th edition (2003), Merriam-Webster Inc., New York
38. Miniussi C., Bonato C., Bignotti S., Gazzoli A., Gennarelli M., Pasqualetti P., Tura G.B., Ventriglia M., and Rossini P.M. Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression?. Clin. Neurophysiol. 116 (2005) 1062-1071
39. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
40. Moreno F.A., Gelenberg A.J., Bachar K., and Delgado P.L. Pindolol augmentation of treatment-resistant depressed patients. J. Clin. Psychiatry 58 (1997) 437-439
41. Mosimann U.P., Schmitt W., Greenberg B.D., Kosel M., Muri R.M., Berkhoff M., Hess C.W., Fisch H.U., and Schlaepfer T.E. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. Psychiatry Res. 126 (2004) 123-133
42. Nelsen M.R., and Dunner D.L. Treatment resistance in unipolar depression and other disorders: diagnostic concerns and treatment possibilities. Psychiatry Clin. North Am. 16 (1993) 541-566
43. Nierenberg A.A., and DeCecco L.M. Definitions of AD treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J. Clin. Psychiatry 62 suppl 16 (2001) 5-9
44. Nierenberg A.A., Keck P., Samson J., Rothschild A.J., and Schatzberg A.F. Methodological considerations for the study of treatment-resistant depression. In: Amsterdam J.D. (Ed). Refractory Depression (1991), Raven Press, New York 1-12
45. Nierenberg A.A., Papakostas G.I., Petersen T., Montoya H.D., Worthington J.J., Tedlow J., Alpert J.E., and Fava M. Lithium augmentation of nortriptyline for subjects resistant to multiple ADs. J. Clin. Psychopharmacol. 23 (2003) 92-95
46. O'Reardon J.P., and Amsterdam J.D. Treatment-resistant depression: progress and limitations. Psychiatry Ann. 28 (1998) 633-640
47. O'Reardon J.P., and Amsterdam J.D. Overview of treatment-resistant depression and its management. In: Amsterdam J.D., Hornig M., and Nierenberg A.A. (Eds). Treatment-Resistant Mood Disorders (2001), Cambridge University Press, NY 30-45
48. O'Reardon J.P., Brunswick D.J., and Amsterdam J.D. Treatment-resistant depression in the age of serotonin: evolving strategies. Curr. Opin. Psychiatry 13 (2000) 93-98
49. Padberg F., Zwanzger P., Thoma H., Kathmann N., Haag C., Greenberg B.D., Hampel H., and Moller H.J. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res. 88 (1999) 163-171
50. Padberg F., Zwanzger P., Keck M.E., Kathmann N., Mikhaiel P., Ella R., Rupprecht P., Thoma H., Hampel H., Toschi N., and Moller H.J. Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology 27 (2002) 638-645
51. Parker G. Classifying depression: should paradigms lost be regained?. Am. J. Psychiatry 157 (2000) 1195-1203
52. Pascual-Leone A., Rubio B., Pallardo F., and Catala M.D. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 348 (1996) 233-237
53. Pazzaglia P.J., Post R.M., Ketter T.A., Callahan A.M., Marangell L.B., Frye M.A., George M.S., Kimbrell T.S., Leverich G.S., Cora-Locatelli G., and Luckenbaugh D. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J. Clin. Psychopharmacol. 18 (1998) 404-413
54. Petersen T., Papakostas G.I., Posternak M.A., Kant A., Guyker W.M., Iosifescu D.V., Yeung A.S., Nierenberg A.A., and Fava M. Empirical testing of two models for staging AD treatment resistance. J. Clin. Psychopharmacol. 25 (2005) 336-341
55. Pope H.G., Cohane G.H., Kanayama G., Siegel A.J., and Hudson J.I. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am. J. Psychiatry 160 (2003) 105-111
56. Poirier M.F., and Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br. J. Psychiatry 175 (1999) 12-16
57. Pridmore S. Substitution of rapid transcranial magnetic stimulation treatments for electroconvulsive therapy treatments in a course of electroconvulsive therapy. Depress. Anxiety 12 (2000) 118-123
58. Roose S.P., Glassman A.H., Walsh B.T., and Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am. J. Psychiatry 143 (1986) 345-848
59. Rossini D., Magri L., Lucca A., Giordani S., Smeraldi E., and Zanardi R. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial. J. Clin. Psychiatry 66 (2005) 1569-1575
60. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., and Trivedi M.H. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol. Med. 26 (1996) 477-486
61. Rush A.J., Thase M.E., and Dube S. Research issues in the study of difficult-to-treat depression. Biol. Psychiatry 53 (2003) 743-753
62. Rush A.J., Fava M., Wisniewski S.R., Lavori P.W., Trivedi M.H., Sackeim H.A., Thase M.E., Nierenberg A.A., Quitkin F.M., Kashner T.M., Kupfer D.J., Rosenbaum J.F., Alpert J., Stewart J.W., McGrath P.J., Biggs M.M., Shores-Wilson K., Lebowitz B.D., Ritz L., and Niederehe G. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control. Clin. Trials 25 (2004) 119-142
63. Rush A.J., Marangell L.B., Sackeim H.A., George M.S., Brannan S.K., Davis S.M., Howland R., Kling M.A., Rittberg B.R., Burke W.J., Rapaport M.H., Zajecka J., Nierenberg A.A., Husain M.M., Ginsberg D., and Cooke R.G. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol. Psychiatry 58 (2005) 347-354
64. Rybakowski J.K., Suwalska A., and Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 40 (1999) 134-139
65. Sackeim H.A. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 62 suppl 16 (2001) 10-17
66. Sackeim H.A., Haskett R.F., Mulsant B.H., Thase M.E., Mann J.J., Pettinati H.M., Greenberg R.M., Crowe R.R., Cooper T.B., and Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 285 (2001) 1299-1307
67. Seidman S.N., Miyazaki M., and Roose S.P. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J. Clin. Psychopharmacol. 25 (2005) 584-588
68. Shapira B., Lidsky D., Gorfine M., and Lerer B. Electroconvulsive therapy and resistant depression: clinical implications of seizure threshold. J. Clin. Psychiatry 57 (1996) 32-38
69. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., and Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158 (2001) 131-134
70. Shelton R.C., Williamson D.J., Corya S.A., Sanger T.M., Van Campen L.E., Case M., Briggs S.D., and Tollefson G.D. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66 (2005) 1289-1297
71. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., Racagni G., Zohar J., and Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol. 9 (1999) 83-91
72. Souery D., Lipp O., Massat I., and Mendlewicz J. The characterization and definition of treatment-resistant mood disorders. In: Amsterdam J.D., Hornig M., and Nierenberg A.A. (Eds). Treatment-Resistant Mood Disorders (2001), Cambridge University Press, NY 3-29
73. Su T.P., Huang C.C., and Wei I.H. Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. J. Clin. Psychiatry 66 (2005) 930-937
74. Thase M.E., and Rush A.J. When at first you don't succeed: sequential strategies for AD nonresponders. J. Clin. Psychiatry 58 suppl 13 (1997) 23-29
75. Thase M.E., Rush A.J., Howland R.H., Kornstein S.G., Kocsis J.H., Gelenberg A.J., Schatzberg A.F., Koran L.M., Keller M.B., Russell J.M., Hirschfeld R.M., LaVange L.M., Klein D.N., Fawcett J., and Harrison W. Double-blind switch study of imipramine or sertraline treatment of AD-resistant chronic depression. Arch. Gen. Psychiatry 59 (2002) 233-239
76. van den Broek W.W., Birkenhager T.K., Mulder P.G., Bruijn J.A., and Moleman P. Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. J. Clin. Psychiatry 67 (2006) 263-268